After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more

StreetInsider2021-12-21

After-Hours Stock Movers: Micron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

459

Report

Comment（161）

RW5
·2021-12-21
O
Reply
1
Report
DiAngel
·2021-12-21
Please like. Thank you
Reply
1
Report
flyingfish28
·2021-12-21
Pls like
Reply
3
Report
Cockatoo
·2021-12-21
🧐$Micron Technology(MU)$
Reply
4
Report
Fold Replies
- flyingfish28:
  K
  2021-12-21
  Reply
  Report
Jennycute10
·2021-12-21
Ok
Reply
3
Report
圆圆蔡
·2021-12-21
Like
Reply
1
Report
Jialatsia
·2021-12-21
Meep
Reply
3
Report
Fold Replies
- Cockatoo:
  💵
  2021-12-21
  Reply
  Report
Gladys8jk
·2021-12-21
Ok
Reply
3
Report
MuppyKoh
·2021-12-21
Please like
Reply
5
Report
Fold Replies
- SeLby:
  Ok
  2021-12-21
  Reply
  Report
zhenx
·2021-12-21
Like and comment
Reply
4
Report
Fold Replies
- 圆圆蔡:
  Done
  2021-12-21
  Reply
  Report
- zhenx:
  ok
  2021-12-21
  Reply
  Report
- PickleT68:
  Done
  2021-12-21
  Reply
  Report
Arnoldy
·2021-12-21
Like
Reply
4
Report
Fold Replies
- calebxiong:
  ok
  2021-12-21
  Reply
  Report
- zhenx:
  ok
  2021-12-21
  Reply
  Report
ew1202
·2021-12-21
Go micron
Reply
3
Report
KxC
·2021-12-21
[Smile]
Reply
1
Report
JLBW
·2021-12-21
Pls like
Reply
8
Report
DSYH
·2021-12-21
Like pls
Reply
6
Report
ChrisLiew
·2021-12-21
Like and comment pls
Reply
5
Report
Fold Replies
- JLBW:
  Ok
  2021-12-21
  Reply
  Report
- Kaden0204:
  ok
  2021-12-21
  Reply
  Report
- FreebigmoNeY:
  Ok
  2021-12-21
  Reply
  Report
這次BBQliao_鹹煎餅了
·2021-12-21
thanks for sharing
Reply
4
Report
Fold Replies
- DSYH:
  ok
  2021-12-21
  Reply
  Report
- ChrisLiew:
  [Cool]
  2021-12-21
  Reply
  Report
Natlow
·2021-12-21
Ok
Reply
4
Report
Fold Replies
- gsz:
  ok
  2021-12-21
  Reply
  Report
- Natlow:
  ok
  2021-12-21
  Reply
  Report
JL0904
·2021-12-21
[Strong]
Reply
2
Report
cassan
·2021-12-21
Pls like
Reply
8
Report
Fold Replies
- 杰森杰森OvO:
  👍🏻
  2021-12-21
  Reply
  Report
- ZachLoh:
  K
  2021-12-21
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1102941409?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-12-21 07:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102941409","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","media":"StreetInsider","content":"<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Source Link</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MU","symbol_name":"美光科技","start_time":0,"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","article_id":"1102941409","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","pubTimestamp":1640044036,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MU":"美光科技","NKE":"耐克","ALDX":"Aldeyra Therapeutics Inc","SOPA":"Society Pass Inc"},"translate_title":"下班后股票搬运工：美光、耐克、Aldeyra Therapeutics等","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALDX":0.9,"MU":0.9,"NKE":0.9,"SOPA":0.9},"content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9000891578,"gmtCreate":1640070377445,"gmtModify":1676533500087,"author":{"id":"3582440300426753","authorId":"3582440300426753","name":"RW5","avatar":"https://static.tigerbbs.com/1892f1a4f1e18bdabb9f243266c5c6b3","vip":1,"hat":"https://static.tigerbbs.com/1c1eed764d9c7ff83dc093fbb9a96bc2","crmLevel":2,"crmLevelSwitch":0,"idStr":"3582440300426753","authorIdStr":"3582440300426753"},"htmlText":"O","listText":"O","text":"O","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000891578","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000801449,"gmtCreate":1640060496500,"gmtModify":1676533499867,"author":{"id":"4100833454173050","authorId":"4100833454173050","name":"DiAngel","avatar":"https://community-static.tradeup.com/news/f7c2ee91188421bf874cdbc97fb77886","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4100833454173050","authorIdStr":"4100833454173050"},"htmlText":"Please like. Thank you&nbsp;","listText":"Please like. Thank you&nbsp;","text":"Please like. Thank you","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000801449","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000800140,"gmtCreate":1640057667984,"gmtModify":1676533499789,"author":{"id":"3559187437759047","authorId":"3559187437759047","name":"flyingfish28","avatar":"https://static.tigerbbs.com/75507aa8ddf5c1cc85f50faf9c40aa31","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3559187437759047","authorIdStr":"3559187437759047"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000800140","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":693571191,"gmtCreate":1640054488738,"gmtModify":1676532396950,"author":{"id":"4095668241594670","authorId":"4095668241594670","name":"Cockatoo","avatar":"https://static.tigerbbs.com/0055bde0938dcc9ff3f3925ff22ea2c7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4095668241594670","authorIdStr":"4095668241594670"},"htmlText":"🧐<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a>","listText":"🧐<a href=\"https://laohu8.com/S/MU\">$Micron Technology(MU)$</a>","text":"🧐$Micron Technology(MU)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/693571191","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100011068,"gmtCreate":1640057678602,"gmtModify":1663241437735,"authorId":3559187437759047,"author":{"id":3559187437759047,"idStr":"3559187437759047","authorId":3559187437759047,"name":"flyingfish28","avatar":"https://static.tigerbbs.com/75507aa8ddf5c1cc85f50faf9c40aa31","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693571191,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"CN"},{"id":9000178062,"gmtCreate":1640053774896,"gmtModify":1676533499645,"author":{"id":"4102050563512520","authorId":"4102050563512520","name":"Jennycute10","avatar":"https://static.tigerbbs.com/507cee5d2260759c49e3dd1dac8ecb9d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4102050563512520","authorIdStr":"4102050563512520"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000178062","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9000147937,"gmtCreate":1640051718742,"gmtModify":1676533499457,"author":{"id":"4091880747410340","authorId":"4091880747410340","name":"圆圆蔡","avatar":"https://static.tigerbbs.com/b8ece9094241ddb84f16eb579a180376","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4091880747410340","authorIdStr":"4091880747410340"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000147937","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":693568636,"gmtCreate":1640050916126,"gmtModify":1676532395612,"author":{"id":"4087959350378170","authorId":"4087959350378170","name":"Jialatsia","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"4087959350378170","authorIdStr":"4087959350378170"},"htmlText":"Meep","listText":"Meep","text":"Meep","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/693568636","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7062636,"gmtCreate":1640054501473,"gmtModify":1663238984738,"authorId":4095668241594670,"author":{"id":4095668241594670,"idStr":"4095668241594670","authorId":4095668241594670,"name":"Cockatoo","avatar":"https://static.tigerbbs.com/0055bde0938dcc9ff3f3925ff22ea2c7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693568636,"type":1,"supId":0,"prevId":0,"content":"💵","text":"💵","html":"💵"}],"langContent":"CN"},{"id":693561748,"gmtCreate":1640050880980,"gmtModify":1676532395597,"author":{"id":"4094787128284850","authorId":"4094787128284850","name":"Gladys8jk","avatar":"https://static.tigerbbs.com/789bbf473867763cd44be080e269826d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094787128284850","authorIdStr":"4094787128284850"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/693561748","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":693532834,"gmtCreate":1640048465150,"gmtModify":1676532394819,"author":{"id":"3585354270249282","authorId":"3585354270249282","name":"MuppyKoh","avatar":"https://static.tigerbbs.com/280b63f52e5976fb134c31bfb22ec07d","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3585354270249282","authorIdStr":"3585354270249282"},"htmlText":"Please like","listText":"Please like","text":"Please like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/693532834","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061936,"gmtCreate":1640050848432,"gmtModify":1663238984732,"authorId":3583197598199652,"author":{"id":3583197598199652,"idStr":"3583197598199652","authorId":3583197598199652,"name":"SeLby","avatar":"https://static.tigerbbs.com/ad7f9d9a13a537bcb9c5ad29a65aa424","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.30","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693532834,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":693532922,"gmtCreate":1640048443673,"gmtModify":1676532394806,"author":{"id":"3575252907553393","authorId":"3575252907553393","name":"zhenx","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3575252907553393","authorIdStr":"3575252907553393"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/693532922","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100010784,"gmtCreate":1640051744786,"gmtModify":1663241433949,"authorId":4091880747410340,"author":{"id":4091880747410340,"idStr":"4091880747410340","authorId":4091880747410340,"name":"圆圆蔡","avatar":"https://static.tigerbbs.com/b8ece9094241ddb84f16eb579a180376","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693532922,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"},{"id":7065743,"gmtCreate":1640082222611,"gmtModify":1663238997534,"authorId":3575252907553393,"author":{"id":3575252907553393,"idStr":"3575252907553393","authorId":3575252907553393,"name":"zhenx","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693532922,"type":1,"supId":7061809,"prevId":0,"content":"ok","text":"ok","html":"ok"},{"id":7061809,"gmtCreate":1640050342286,"gmtModify":1663238985336,"authorId":3581915827887523,"author":{"id":3581915827887523,"idStr":"3581915827887523","authorId":3581915827887523,"name":"PickleT68","avatar":"https://static.tigerbbs.com/8fce28b8d12bdeb2997c5098f8b8e413","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693532922,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"CN"},{"id":693536458,"gmtCreate":1640048431502,"gmtModify":1676532394804,"author":{"id":"3577504972179170","authorId":"3577504972179170","name":"Arnoldy","avatar":"https://static.tigerbbs.com/3bfdb559c890249bf261380cb2bd5721","vip":1,"hat":"https://static.tigerbbs.com/a3dee1aa3a3a3c1814833a4d3f8a5669","crmLevel":2,"crmLevelSwitch":0,"idStr":"3577504972179170","authorIdStr":"3577504972179170"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/693536458","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061348,"gmtCreate":1640048451355,"gmtModify":1663238979339,"authorId":3573369466096628,"author":{"id":3573369466096628,"idStr":"3573369466096628","authorId":3573369466096628,"name":"calebxiong","avatar":"https://static.tigerbbs.com/08d48582a3126a51d85cbec3a72f9923","vip":1,"crmLevel":9,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693536458,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":7061350,"gmtCreate":1640048453216,"gmtModify":1663238978863,"authorId":3575252907553393,"author":{"id":3575252907553393,"idStr":"3575252907553393","authorId":3575252907553393,"name":"zhenx","avatar":"https://static.tigerbbs.com/62a4767b8928f124a0f7f02bd3c21f62","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693536458,"type":1,"supId":0,"prevId":0,"content":"ok","text":"ok","html":"ok"}],"langContent":"CN"},{"id":693536148,"gmtCreate":1640048395206,"gmtModify":1676532394798,"author":{"id":"3577091643764482","authorId":"3577091643764482","name":"ew1202","avatar":"https://static.tigerbbs.com/39fd4df438885b50c79f4ae10e1a8ed0","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3577091643764482","authorIdStr":"3577091643764482"},"htmlText":"Go micron","listText":"Go micron","text":"Go micron","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/693536148","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":9000143394,"gmtCreate":1640048394401,"gmtModify":1676533499307,"author":{"id":"3573815740841721","authorId":"3573815740841721","name":"KxC","avatar":"https://static.tigerbbs.com/22fcf560e8b13e0bc2501c1f0f3f3488","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":8,"crmLevelSwitch":1,"idStr":"3573815740841721","authorIdStr":"3573815740841721"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000143394","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":693536975,"gmtCreate":1640048371905,"gmtModify":1676532394753,"author":{"id":"4088639231266520","authorId":"4088639231266520","name":"JLBW","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4088639231266520","authorIdStr":"4088639231266520"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/693536975","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":693536059,"gmtCreate":1640048367608,"gmtModify":1676532394753,"author":{"id":"3576529744197419","authorId":"3576529744197419","name":"DSYH","avatar":"https://static.tigerbbs.com/1b1ab721d954c8f8215155b381c73f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3576529744197419","authorIdStr":"3576529744197419"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/693536059","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":693538545,"gmtCreate":1640048347618,"gmtModify":1676532394744,"author":{"id":"3580393689769738","authorId":"3580393689769738","name":"ChrisLiew","avatar":"https://static.tigerbbs.com/35b3b9b772013ce79f9f4c5318d46fa7","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":2,"crmLevelSwitch":1,"idStr":"3580393689769738","authorIdStr":"3580393689769738"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/693538545","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061331,"gmtCreate":1640048387483,"gmtModify":1663238982929,"authorId":4088639231266520,"author":{"id":4088639231266520,"idStr":"4088639231266520","authorId":4088639231266520,"name":"JLBW","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538545,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":7061327,"gmtCreate":1640048360114,"gmtModify":1663238981629,"authorId":4097384260129050,"author":{"id":4097384260129050,"idStr":"4097384260129050","authorId":4097384260129050,"name":"Kaden0204","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538545,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":7061343,"gmtCreate":1640048440905,"gmtModify":1663238979333,"authorId":3578472903237510,"author":{"id":3578472903237510,"idStr":"3578472903237510","authorId":3578472903237510,"name":"FreebigmoNeY","avatar":"https://static.tigerbbs.com/3a31b93448657f6d83ec000012f9f9e6","vip":1,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538545,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":693538233,"gmtCreate":1640048344429,"gmtModify":1676532394735,"author":{"id":"3555385471829073","authorId":"3555385471829073","name":"這次BBQliao_鹹煎餅了","avatar":"https://static.tigerbbs.com/f7ab83fa2cfc43af0bc458b43eca1ebb","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3555385471829073","authorIdStr":"3555385471829073"},"htmlText":"thanks for sharing","listText":"thanks for sharing","text":"thanks for sharing","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/693538233","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061329,"gmtCreate":1640048375282,"gmtModify":1663238982143,"authorId":3576529744197419,"author":{"id":3576529744197419,"idStr":"3576529744197419","authorId":3576529744197419,"name":"DSYH","avatar":"https://static.tigerbbs.com/1b1ab721d954c8f8215155b381c73f72","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538233,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":7061328,"gmtCreate":1640048370885,"gmtModify":1663238981546,"authorId":3580393689769738,"author":{"id":3580393689769738,"idStr":"3580393689769738","authorId":3580393689769738,"name":"ChrisLiew","avatar":"https://static.tigerbbs.com/35b3b9b772013ce79f9f4c5318d46fa7","vip":1,"currentWearingBadge":{"badgeId":"82ffa69a97264fba9002044f4f5f535b-1","templateUuid":"82ffa69a97264fba9002044f4f5f535b","name":"Tiger Think Tank","description":"Tiger Think Tank","bigImgUrl":"https://community-static.tradeup.com/news/193f8255673f42bdc610097b2074ec3e","smallImgUrl":"https://community-static.tradeup.com/news/06af124f59f026a383d35b268362424f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.06","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":4001},"crmLevel":2,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538233,"type":1,"supId":0,"prevId":0,"content":"[Cool]","text":"[Cool]","html":"[Cool]"}],"langContent":"CN"},{"id":693538812,"gmtCreate":1640048309499,"gmtModify":1676532394718,"author":{"id":"3580161027656510","authorId":"3580161027656510","name":"Natlow","avatar":"https://static.tigerbbs.com/14a777947812993c0fa2085832de2e68","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3580161027656510","authorIdStr":"3580161027656510"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/693538812","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":7061323,"gmtCreate":1640048349297,"gmtModify":1663238983129,"authorId":3568243121821953,"author":{"id":3568243121821953,"idStr":"3568243121821953","authorId":3568243121821953,"name":"gsz","avatar":"https://static.tigerbbs.com/9d9d2a871f9324a5f8055fe44ab9b8b5","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538812,"type":1,"supId":7061319,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"},{"id":7061319,"gmtCreate":1640048315670,"gmtModify":1663238982145,"authorId":3580161027656510,"author":{"id":3580161027656510,"idStr":"3580161027656510","authorId":3580161027656510,"name":"Natlow","avatar":"https://static.tigerbbs.com/14a777947812993c0fa2085832de2e68","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538812,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":9000143094,"gmtCreate":1640048295012,"gmtModify":1676533499291,"author":{"id":"3581486608092488","authorId":"3581486608092488","name":"JL0904","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3581486608092488","authorIdStr":"3581486608092488"},"htmlText":"[Strong]&nbsp;","listText":"[Strong]&nbsp;","text":"[Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9000143094","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":693538024,"gmtCreate":1640048292932,"gmtModify":1676532394744,"author":{"id":"3562891229203554","authorId":"3562891229203554","name":"cassan","avatar":"https://static.tigerbbs.com/2f12a58ed338611b5e581e7f21ac579b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"3562891229203554","authorIdStr":"3562891229203554"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/693538024","repostId":1102941409,"repostType":4,"repost":{"id":"1102941409","kind":"news","pubTimestamp":1640044036,"share":"https://ttm.financial/m/news/1102941409?lang=&edition=fundamental","pubTime":"2021-12-21 07:47","market":"us","language":"en","title":"After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more","url":"https://stock-news.laohu8.com/highlight/detail?id=1102941409","media":"StreetInsider","summary":"Micron Technology +6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.Nike +3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter ca","content":"<p>After-Hours Stock Movers:</p>\n<p>Micron Technology (NASDAQ:MU)<b>+6.6%</b>; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.</p>\n<p>Nike (NYSE:NKE)<b>+3.4%</b>; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.</p>\n<p>Aldeyra Therapeutics (NASDAQ:ALDX)<b>-39%</b>; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p&lt;0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.</p>\n<p>Society Pass (NASDAQ: SOPA)<b>-11.8%</b>; Climbed 240% intraday.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Micron,Nike,Aldeyra Therapeutics and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-21 07:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the ...</p>\n\n<a href=\"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ALDX":"Aldeyra Therapeutics Inc","NKE":"耐克","MU":"美光科技","SOPA":"Society Pass Inc"},"source_url":"https://www.streetinsider.com/Special+Reports/After-Hours+Stock+Movers+1220%3A+%28MU%29+%28NKE%29+%28ALDX%29+%28SOPA%29/19375559.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102941409","content_text":"After-Hours Stock Movers:\nMicron Technology (NASDAQ:MU)+6.6%; reported Q1 EPS of $2.16, $0.05 better than the analyst estimate of $2.11. Revenue for the quarter came in at $7.69 billion versus the consensus estimate of $7.67 billion. GUIDANCE: Micron Technology sees Q2 2022 EPS of $1.85-$2.05, versus the consensus of $1.86. Micron Technology sees Q2 2022 revenue of $7.3-7.7 billion, versus the consensus of $7.27 billion.\nNike (NYSE:NKE)+3.4%; reported Q2 EPS of $0.83, $0.20 better than the analyst estimate of $0.63. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.25 billion.\nAldeyra Therapeutics (NASDAQ:ALDX)-39%; announced top-line results from the Phase 3 TRANQUILITY Trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational product candidate for the treatment of dry eye disease. Although the primary endpoint of ocular redness was not met in TRANQUILITY, statistical significance (p=0.0001) was achieved for the dry eye disease sign of Schirmer test, a secondary endpoint. Statistical significance (p<0.0001) was also achieved for the post-hoc assessment of Schirmer test responders of ≥10 mm.\nSociety Pass (NASDAQ: SOPA)-11.8%; Climbed 240% intraday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":100010512,"gmtCreate":1640048393860,"gmtModify":1663241436935,"authorId":4088596505254670,"author":{"id":4088596505254670,"idStr":"4088596505254670","authorId":4088596505254670,"name":"杰森杰森OvO","avatar":"https://static.tigerbbs.com/8dd96217e20c4a5496797a3224aba559","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538024,"type":1,"supId":0,"prevId":0,"content":"👍🏻","text":"👍🏻","html":"👍🏻"},{"id":7061316,"gmtCreate":1640048299973,"gmtModify":1663238981453,"authorId":3569225668665653,"author":{"id":3569225668665653,"idStr":"3569225668665653","authorId":3569225668665653,"name":"ZachLoh","avatar":"https://static.tigerbbs.com/39ae35b0a4b7e22dee7378b1bc1de2f6","vip":1,"currentWearingBadge":{"badgeId":"23f878ed27704312ae41c7f17e73b319-6","templateUuid":"23f878ed27704312ae41c7f17e73b319","name":"Annualised return","description":"Top 3%","bigImgUrl":"https://community-static.tradeup.com/news/6fbaa8e552e02eae8e6a2ce5d6566431","smallImgUrl":"https://community-static.tradeup.com/news/98862e418516dab972bed7aaf561dec6","grayImgUrl":"https://community-static.tradeup.com/news/3a5ca933a5695ed2e862b228f6c09ee5","redirectLinkEnabled":0,"redirectLink":"https://www.tigerbrokers.com.sg/activity/market/2023/stock-contest?adcode=StockContest2023","hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.30","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":5300},"crmLevel":7,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":693538024,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":459,"commentSize":161,"repostSize":0,"favoriteSize":2,"likeStatus":false,"favoriteStatus":false}}